Why 40–60% of people with OCD don’t respond to standard treatment
OCD’s neurobiology extends beyond serotonin to include glutamate—a brain chemical involved in learning and memory—and hyperactive neural circuits that create rigid obsessive loops SSRIs alone cannot address. This explains why 40-60% of people with OCD don’t achieve meaningful symptom relief from selective serotonin reuptake inhibitors (SSRIs), even at optimized doses and durations, making OCD treatment when SSRIs fail a critical clinical concern.
The brain communication loops involved in OCD are more complex than initially understood when SSRIs became standard treatment. While SSRIs increase serotonin availability, glutamate—the brain’s most abundant excitatory neurotransmitter—plays a central role in compulsive behaviors. When these circuits fire repeatedly, they create the “stuck” feeling many people describe—thoughts that won’t quiet and compulsions that feel impossible to resist through willpower alone.
Access to evidence-based care compounds this challenge. Many adults wait years before receiving an accurate diagnosis, and even after diagnosis, fewer than 20% receive cognitive behavioral therapy . Exposure and response prevention (ERP)—the gold-standard psychological treatment where people gradually face feared situations without performing compulsions—remains dramatically underutilized. This care gap leaves countless individuals cycling through medications without the therapeutic support that could make those medications more effective.
When SSRIs don’t provide adequate relief, people may feel they have “failed” treatment when in reality the standard of care has biological limitations that alternative mechanisms can address. Treatment-resistant OCD isn’t a reflection of insufficient effort—it’s a signal that the biological pathways maintaining symptoms require tools beyond what serotonin modulation alone can provide. Nushama’s clinical team recognizes this gap and offers evidence-based alternatives that target different brain systems to create pathways toward relief.
The 2026 landscape of alternative treatments for OCD
Four main treatment pathways have emerged for people whose symptoms haven’t responded to SSRIs and standard ERP: FDA-cleared brain stimulation, off-label medications targeting glutamate, experimental psychedelic research, and adjunctive behavioral interventions. Each offers distinct biological mechanisms, evidence grades, and practical considerations for sequencing care.
Deep TMS: FDA-cleared brain stimulation for OCD
Deep transcranial magnetic stimulation (TMS) is FDA-cleared specifically for OCD and uses magnetic pulses to reach deeper brain structures—the medial prefrontal cortex and anterior cingulate cortex—gradually reducing overactive circuits over repeated sessions. The BrainsWay protocol received clearance in 2018 as the first noninvasive device specifically approved for OCD treatment.
The technology generates brief magnetic fields that pass through the skull and induce small electrical currents in targeted brain regions, essentially “tuning down” circuits stuck in repetitive loops. Unlike earlier approaches with limited depth penetration, the H7-coil configuration reaches structures several centimeters beneath the scalp. Sessions last about 20 minutes with no anesthesia needed.
The pivotal clinical trial demonstrated that 38.1% of participants in the active TMS group achieved a clinically significant response (greater than 30% reduction on the Yale-Brown Obsessive Compulsive Scale) compared to just 11.1% in the sham group. Treatment typically involves 30 daily sessions over six weeks. In 2026, accelerated protocols like the SAINT protocol—delivering multiple sessions per day over one week—are emerging in research settings, though the six-week standard remains most widely available.
Most members don’t notice substantial changes in the first week. Symptom reduction typically becomes apparent around week three, with continued improvement through the full course. Daily sessions mean arranging transportation and taking time from work for six consecutive weeks, which can be challenging for some schedules.
Ketamine vs TMS for OCD: different mechanisms, different timelines
Ketamine disrupts rigid thought loops at the chemical level within hours of a single infusion, while TMS gradually reduces hyperactivity through repeated sessions over weeks as described above. Intravenous (IV) ketamine modulates glutamate, creating rapid relief that’s particularly valuable for people experiencing severe functional impairment.
The landmark 2013 randomized controlled trial by Rodriguez and colleagues published in Neuropsychopharmacology, demonstrated that participants receiving ketamine showed significant rapid reduction in obsessions during the infusion that persisted for one week post-treatment.
Ketamine acts as an NMDA receptor antagonist—blocking specific glutamate receptors and triggering downstream effects that alter how neurons communicate. This appears to “unlock” rigid circuits, creating what many people describe as sudden clarity or lifting of mental fog. The obsessive thoughts that dominated consciousness become quieter and less commanding.
While TMS holds FDA clearance specifically for OCD, ketamine is used off-label—meaning prescribed for a condition other than its original FDA approval, which is common and legal in psychiatry when supported by research. Ketamine protocols typically consist of 4-6 infusions over 2-3 weeks, with each session lasting about 90 minutes including preparation and monitoring.
The practical treatment commitment differs substantially: TMS requires consistent daily availability for six consecutive weeks, while ketamine’s shorter course may be more feasible for people with work or caregiving responsibilities. Both require medical supervision, but they can also be combined or sequenced—some members begin with one approach and later add the other if partial response suggests room for additional benefit.
Emerging OCD treatments: psilocybin research and esketamine
Psilocybin shows early promise for OCD in clinical trials, and esketamine (Spravato) offers an FDA-approved nasal spray formulation of ketamine, though each has distinct limitations. Psilocybin—the active compound in certain mushrooms—remains restricted to research settings despite Phase 3 trials underway at Yale School of Medicine and Centre for Addiction and Mental Health. Early-phase studies have explored single-dose psilocybin sessions paired with psychological support, with participants reporting shifts in their relationship to intrusive thoughts and renewed sense of agency over compulsive behaviors. However, psilocybin remains a Schedule I controlled substance under federal law and is not available in standard clinical practice.
Esketamine is FDA-approved specifically for treatment-resistant depression and acute suicidal ideation. While some clinicians have explored its use for OCD, the intranasal route provides less precise dosing and less control over blood levels compared to IV administration. For OCD specifically, research evidence centers on IV ketamine protocols rather than intranasal esketamine.
The pharmacokinetic differences matter clinically. Intranasal absorption creates variable blood levels depending on nasal anatomy. IV administration delivers ketamine directly into the bloodstream at a controlled rate, producing predictable brain concentrations that clinicians can adjust mid-session if needed. This precision is particularly valuable for OCD, where the temporary altered state during ketamine sessions—called dissociation, where thoughts and sensations feel dreamlike or disconnected—can initially feel unsettling for people who fear losing control.
For people seeking treatment now rather than waiting for future research outcomes, IV ketamine offers a legally accessible option with established evidence and medical supervision that meets current clinical standards.
Additional approaches: neurofeedback and exercise as adjuncts
Neurofeedback and exercise both show preliminary evidence as complementary tools, though neither replaces medical intervention or first-line therapy. Neurofeedback—using real-time brain activity monitoring to help people learn to regulate their own neural patterns—has shown early results. A double-blind trial published in Psychiatry Research targeting the anterior prefrontal cortex found the active neurofeedback group achieved greater reduction in compulsions compared to sham feedback (56% vs. 21%), though sample sizes remain small.
Exercise shows more consistent support. A systematic review in Psychiatry Research of six randomized trials found that regular aerobic exercise was associated with large reductions in OCD symptoms, with additional benefits for co-occurring anxiety and depression. While exercise alone is not sufficient to replace medical treatment, incorporating movement into a comprehensive care plan—particularly during the integration phase after ketamine—supports overall recovery and may enhance the brain’s ability to form new connections.
Building a treatment-resistant OCD strategy
Strategic sequencing of therapies—rather than random trial-and-error—creates the conditions where behavioral therapy can finally take hold. The most effective strategies follow a stepped-care model: optimize standard approaches first, add augmentation when needed, then escalate to neuromodulation or ketamine-assisted therapy while timing behavioral work to leverage each intervention’s unique mechanism.
Start with optimization, then escalate systematically
Optimize SSRIs at adequate doses—often higher than for depression—for sufficient duration (typically 10-12 weeks) combined with weekly ERP sessions before moving to newer interventions. Research shows that one-third of non-responders to initial SSRI trials will respond to augmentation with low-dose antipsychotic medication or a switch to clomipramine.
Effective SSRI doses for OCD typically exceed those used for depression—fluoxetine may require 60-80 mg daily, sertraline 200-300 mg, and paroxetine 60 mg. Many people are maintained on doses appropriate for depression but inadequate for OCD, creating the false impression of treatment resistance when the issue is simply underdosing.
If optimization and augmentation haven’t produced meaningful improvement after several months, neuromodulation and ketamine-assisted therapy represent logical next steps. The choice between TMS and ketamine often depends on symptom severity, functional impairment, and how quickly relief is needed. Ketamine creates a distinct strategic advantage through neuroplasticity enhancement—the brain’s ability to form new connections and rewire established patterns.
How ketamine creates space for ERP to work
Ketamine addresses a fundamental barrier to ERP success: the overwhelming anxiety that makes exposure exercises feel impossible. When obsessive thoughts trigger intense distress, asking someone to purposefully face their fears without performing compulsions can feel unbearable no matter how skilled the therapist or motivated the person.
Ketamine works through a dual mechanism. First, it provides rapid reduction in baseline anxiety and intrusive thought frequency, creating what members often describe as “breathing room” to engage with therapeutic work. Second, ketamine promotes neuroplasticity—the brain’s ability to form new connections and rewire established patterns—by activating specific molecular pathways that strengthen communication between brain cells and support the survival and growth of neurons.
This neuroplastic window lasts approximately 24-72 hours after an infusion. During this period, the brain is particularly receptive to new learning—essentially more “moldable” than usual. Combining ketamine with ERP means scheduling the hardest exposure exercises within this window, when both biological and psychological conditions are optimized for breaking old patterns. The medication reduces the mental “noise” of intrusive thoughts while simultaneously making the brain more capable of learning that feared situations are actually safe.
This isn’t about replacing ERP—it’s about removing the barriers that prevented ERP from working in the first place. Some members experience dissociation during ketamine sessions, which can initially feel unsettling for people with OCD who fear loss of control. However, this dissociative state appears connected to ketamine’s therapeutic effects, and starting at lower doses before escalating to standard doses may enhance tolerability.
What integration therapy provides beyond the infusion
Integration therapy—the structured process of making sense of ketamine experiences and translating temporary symptom relief into sustained behavioral shifts—helps members process insights and plan for maintaining gains as medication effects naturally taper. The medication itself creates a biological opportunity, but integration sessions help members translate that opportunity into lasting change.
Integration work typically includes structured reflection on thoughts and feelings that arose during the session, identification of patterns or beliefs that sustain compulsive behaviors, and concrete planning for maintaining gains. Journaling helps solidify new perspectives, movement practices support brain health and stress regulation, and mindfulness techniques strengthen the ability to observe intrusive thoughts without automatically responding with compulsions.
For members working with existing therapists, Nushama clinicians coordinate care to ensure ERP homework assignments and integration work reinforce each other. The goal of integration is prevention of relapse. While ketamine can provide profound relief from obsessive symptoms, without behavioral work to address underlying patterns, old habits tend to re-emerge once medication effects fade. Integration creates a bridge between the neurobiological changes ketamine initiates and the psychological changes that make those benefits durable.
Frequently asked questions
The following questions address common concerns about treatment-resistant OCD options, safety protocols, and what to expect from ketamine-assisted therapy at Nushama.
Q: Is ketamine treatment FDA-approved for OCD?
A: No—ketamine is not FDA-approved specifically for OCD; it is used off-label by medical professionals based on clinical trial evidence. Off-label use—prescribing a medication for a condition other than its original approval—is common in psychiatry and is legal when supported by research. Learn more about ketamine’s FDA status and how off-label use serves people with treatment-resistant conditions.
Q: Can I continue seeing my current therapist during ketamine treatment?
A: Yes—collaboration with your existing care team is strongly encouraged and often essential to success. Nushama clinicians communicate directly with members’ therapists (with your permission) to coordinate timing of ERP sessions within the neuroplastic window and align treatment goals. Many members find that ketamine finally allows them to engage with therapeutic techniques their therapist has been recommending for months or years.
Q: How is ketamine different from SSRIs for OCD?
A: SSRIs work by increasing serotonin availability in the brain and typically require 8-12 weeks of daily dosing before symptom improvement appears. Ketamine modulates glutamate—a different neurotransmitter system entirely—and can reduce obsessive symptoms within hours of a single infusion. This rapid-onset mechanism offers a fundamentally different option for people whose brain chemistry hasn’t responded to serotonin-based approaches.
Q: What if I have tried ERP and it didn’t work for me?
A: Many people find that severe baseline anxiety makes ERP exercises emotionally inaccessible—the exposure feels too overwhelming to complete even with a skilled therapist’s support. Ketamine may lower that anxiety enough to make previously intolerable exposures feel manageable, allowing the learning process of ERP to finally take hold. Members often report being able to “sit with” uncomfortable thoughts and sensations during the neuroplastic window in ways they couldn’t before.
Q: Will the effects of ketamine last, or do I need ongoing sessions?
A: Evidence from the Rodriguez trial showed sustained reduction in obsessive thoughts for at least one week following a single ketamine infusion. The durability of benefits varies among individuals and is significantly enhanced through integration therapy and behavioral work during the neuroplastic window. Some members experience lasting relief after an initial series of 4-6 infusions paired with intensive ERP, while others benefit from periodic booster sessions spaced weeks or months apart. Explore Nushama’s treatment protocols and pricing to understand typical course length and follow-up options.
Q: What safety protocols ensure ketamine treatment is medically supervised?
A: Every ketamine session at Nushama begins with medical screening to confirm current safety for treatment—including vital sign checks, medication review, and psychological state assessment. Licensed clinicians administer precise IV doses calculated for each person’s weight and medical history. Throughout the 45-60 minute infusion, continuous monitoring tracks heart rate, blood pressure, and oxygen levels while a clinician remains present to support the psychological experience. Post-session observation ensures stable vital signs and clear-headedness before discharge, and members receive 24/7 access to clinical support if questions or concerns arise between sessions.
If standard SSRIs and ERP haven’t brought the relief you deserve, the 2026 treatment landscape offers evidence-based alternative treatments for OCD with distinct mechanisms and rapid timelines. Nushama provides IV ketamine-assisted therapy within a comprehensive model that includes psychiatric evaluation, dosing protocols informed by OCD-specific research, and integration support to help you translate temporary symptom relief into durable behavioral change. Schedule a consultation with Nushama’s care team to explore whether ketamine-assisted therapy may support your path forward—and discover what to expect during the journey from initial assessment through integration.
